Cell therapy research publication RegMedNet has just posted HemaCare’s latest article on how to use apheresis and cell collection techniques to optimize starting material quality. 
An Expansive Donor Network Helps Guarantee Consistent Quality
Apheresis donor material is intrinsically variable, yet a successful cell therapy product must have consistent efficacy across a wide range of patients. How do we reconcile these realities? As a large-scale apheresis supplier, HemaCare understands that quality raw materials are a matter of careful planning and expertise. Inter-donor variability can impact critical parameters including cell collection volume, cell subtype composition and cell proliferation potential.  Each of these parameters impact apheresis unit potency, and can impact resource use and manufacturing efficiency.